Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL17065242 | 0.94 | DNMT1 (0.34) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL242425 | 0.89 | DNMT1 (0.41) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL9011631 | 0.84 | TP53 (0.37) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL9798150 | 0.84 | TP53 (0.37) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL1961248 | 0.82 | DNMT1 (0.39) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL8741891 | 0.82 | DNMT1 (0.39) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL7938206 | 0.82 | LMNA (0.38) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL11350903 | 0.82 | HTT (0.42) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL11428634 | 0.82 | DNMT1 (0.41) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL5800741 | 0.82 | DNMT1 (0.41) | DNMT1TP53MAPTSTAT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265046-B2 | Method of making a solder ball | NEOMAX MATERIAL CO., LTD. (JP) | 2007-09-04 | — | — | US | claimed |
| US-20260071264-A1 | USE OF HETEROAROMATIC RING COMPOUNDS IN NUCLEIC ACID DETECTION | BGI SHENZHEN (CN) | 2026-03-12 | — | — | US | disclosed |
| WO-2023018232-A1 | BEAD COMPLEX FOR DETECTING NUCLEIC ACID MOLECULE IN BIOLOGICAL SAMPLE AND METHOD FOR DETECTING NUCLEIC ACID USING SAME | 주식회사 에스엠엘제니트리 | 2023-02-16 | — | — | WO | disclosed |
| EP-3705601-A1 | ELECTROLESS GOLD PLATING BATH | C. Uyemura & Co., Ltd. (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-7569164-B2 | Solder precoating method | HARIMA CHEMICALS, INC. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080179383-A1 | Solder paste composition and solder precoating method | HARIMA CHEMICALS, INC. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-5536795-A | ADHESIVES AND PAINTS AND FIREPROOFING THERMOSETTING RESINS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1996-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071264-A1 | USE OF HETEROAROMATIC RING COMPOUNDS IN NUCLEIC ACID DETECTION | POLN, POLRMT, POLH | DNMT1 186/4885TP53 321/4885MAPT 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.